Giuseppe Curigliano, MD, PhD, Professor at University of Milan and Head of Phase I Division at IEO, ESMO President Elect, Tweets are my own
Milan, Italy
Joined June 2015
- Tweets4.9K
- Following1.4K
- Followers8.1K
- Likes5.6K
G Curigliano MD PhD retweeted
🧬 What if ADCs do more than deliver cytotoxic payloads?
🎯Our new Review in @NatRevClinOncol explores how ADCs shape antitumour immunity
and inform new therapeutic strategies
A pleasure to work with @curijoey, @DrLisaCarey, @antoniomarraMD and @darioT_
🔗 nature.com/articles/s41571-0…
G Curigliano MD PhD retweeted
His contributions have revolutionized breast cancer treatment.
Charles M. Perou, PhD, will receive the 2026 William L. McGuire Memorial Lecture Award at #SABCS26 in recognition of his pioneering research in cancer genomics and breast cancer biology. He will deliver his award lecture on Thursday, Dec. 10, at 9 AM CT. bit.ly/4j8Xd70
Don’t miss the data at #ESMO2026!!!!!
Positive phase 3 data for adjuvant pembro +/- personalized mRNA-based neoantigen vaccine for melanoma just announced by Merck and Moderna. Welcome to the future! merck.com/news/merck-and-mod…
Don’t miss the data at #ESMO2026
JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯
Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma.
For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy.
Personalized cancer vaccines are moving from promise to reality.
Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏
Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (nature.com/articles/s41586-0…)
merck.com/news/merck-and-mod…
G Curigliano MD PhD retweeted
@curijoey don’t forget the most important thing to try when traveling to Sicily…La granita con la brioche 😁
G Curigliano MD PhD retweeted
Dear G, my relance with Voidokoilia, Pylos, at the Odysseus landing site
If you ever find yourself visiting Italy, discover a truly unique and unforgettable place.
✨ Come and experience Taormina, where breathtaking beauty, crystal-clear waters, and nature come together in one extraordinary setting.
G Curigliano MD PhD retweeted
🎙️@PBarataMD of @UHhospitals and @curijoey of @myESMO discuss the next era of ADCs and challenges with sequencing, target selection, and resistance on the latest episode of #BytheBook Podcast: bit.ly/4puz7Vg
#ASCOEdBook.
G Curigliano MD PhD retweeted
Pr. Curigliano @curijoey in @CityOfBoston @DanaFarber with the @DFCI_BreastOnc group to deliver the Schlager lecture ! With @DrHBurstein @PTarantinoMD @EMittendorfMD @elmayermd, Dr Ana Garrido-Castro et al! Great time !
Giuseppe Curigliano, MD, PhD (@curijoey), our keynote speaker delivering the Schlager Lecture on Sequencing Novel Therapies in the Modern Era – Implications for Clinical Trial Design. #DanaFarberBreastCancerCourse
G Curigliano MD PhD retweeted
Paolo Tarantino, MD (@PTarantinoMD) closed out the #DanaFarberBreastCancerCourse with a lively discussion on ER+ #MetastaticBreastCancer on ADCs and Beyond.
G Curigliano MD PhD retweeted
Happening now! #DanaFarberBreastCancerCourse: New Horizons, Current Controversies.
Hal Burstein, MD, PhD (@DrHBurstein) and Ana Garrido-Castro, MD welcoming in-person and virtual attendees.
G Curigliano MD PhD retweeted
Ana Garrido-Castro, MD gives an excellent presentation on metastatic triple negative breast cancer focusing on #ADCs and immunotherapy. #DanaFarberBreastCancerCourse #TNBC #MBC
G Curigliano MD PhD retweeted
Stefania Morganti, MD (@StefiMorganti) shares treatment updates on the management of HER2+ Metastatic Breast Cancer, including @DanaFarber recommendations for first-line and maintenance therapy. #DanaFarberBreastCancerCourse #MBC #BreastCancer #bcsm #MetastaticBreastCancer
G Curigliano MD PhD retweeted
Giuseppe Curigliano, MD, PhD (@curijoey), our keynote speaker delivering the Schlager Lecture on Sequencing Novel Therapies in the Modern Era – Implications for Clinical Trial Design. #DanaFarberBreastCancerCourse
G Curigliano MD PhD retweeted
Program underway -- join us now for discussion of systemic therapy for early stage cancer. @curijoey Dr Giuseppe Curigliano (ESMO Pres) will deliver the Schlager Lecture on Novel Therapies in Breast Cancer at 1:15 PM EDT.
Course is free; registration at link below is required.
G Curigliano MD PhD retweeted
🇮🇹 The Milan Summit was meant to be a Breast Cancer focused educational conference. It spontaneously turned out to be so much more.
A high profile, international think tank and consensus gathering, which bridged the bench to the bedside, embracing multiple world continents and touching on the most contemporary open questions in breast oncology.
Huge congrats and thanks to the conference co-chairs @curijoey, @hoperugo and #PaoloMarchetti for envisioning this great conference, and to @FondazioneMen for supporting it.
G Curigliano MD PhD retweeted
So excited to welcome my breast friend @JAMouabbi to 🇮🇹 for the Milan Summit on Breast Cancer. Terrific food for thought on how to navigate treatment of oligometastatic disease in the setting of mixed evidence. You can clearly see that he fully embraced the Italian culture 🤌
